A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Trial Profile

A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Napabucasin (Primary) ; Paclitaxel
  • Indications Advanced breast cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 06 Jun 2017 Results (n=98) assessing clinical safety and anti-cancer activity of napabucasin plus weekly paclitaxel in patients with advanced ovarian cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2017 Safety and efficacy results in patients with thymoma or thymic carcinoma (n=9), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Safety and efficacy results in patients with advanced melanoma (n=12), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top